Intellia Therapeutics (NTLA) slides as investors digest recent earnings and dilution overhang

Intellia Therapeutics (NTLA) is down 8.3% today. Here is some analysis on what might have caused this price movement.

Analysis: The drop appears tied to post-earnings repositioning after Intellia’s recent quarterly update, where collaboration revenue was modest and investors refocused on cash burn and execution timelines. The move may also reflect lingering dilution pressure following the company’s late-April equity offering, which can create a near-term overhang even when it extends runway.

Details:

Intellia’s first-quarter update showed collaboration revenue of about $15.0 million and a net loss of about $96.2 million (diluted loss of $0.81 per share).

Cash, cash equivalents, and marketable securities were about $517.2 million at March 31, 2026, with management indicating existing resources (including the April financing) support operations at least into 2028.

In late April, Intellia priced an underwritten public offering of 16,744,187 shares at $10.75 per share, with expected gross proceeds of roughly $180 million (excluding any overallotment).

Even with positive program updates earlier this spring, the stock can trade sharply on sentiment around funding needs, commercialization buildout, and the timing/risk of late-stage clinical execution.

Sources:

Intellia Therapeutics (Investor Relations / GlobeNewswire), SEC, Zacks

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$NTLA Insider Trading Activity

$NTLA insiders have traded $NTLA stock on the open market 12 times in the past 6 months. Of those trades, 1 have been purchases and 11 have been sales.

Here’s a breakdown of recent trading of $NTLA stock by insiders over the last 6 months:

FRED E COHEN purchased 150,000 shares for an estimated $1,402,500
JOHN M LEONARD (President and CEO) has made 0 purchases and 4 sales selling 122,292 shares for an estimated $1,150,869.
JAMES BASTA (EVP, General Counsel) has made 0 purchases and 2 sales selling 11,608 shares for an estimated $112,443.
DAVID LEBWOHL (EVP, Chief Medical Officer) sold 11,903 shares for an estimated $109,626
ELIANA CLARK (EVP, Chief Technical Officer) sold 9,515 shares for an estimated $87,633
BIRGIT C SCHULTES (EVP, Chief Scientific Officer) sold 8,508 shares for an estimated $78,358
EDWARD J III DULAC (EVP, Chief Financial Officer) sold 6,379 shares for an estimated $58,750
MICHAEL P DUBE (VP, Chief Accounting Officer) sold 2,989 shares for an estimated $27,528

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

EARLY ACCESS

Receive NTLA Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$NTLA Hedge Fund Activity

We have seen 186 institutional investors add shares of $NTLA stock to their portfolio, and 121 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

CONTRARIUS GROUP HOLDINGS LTD removed 5,175,456 shares (-87.9%) from their portfolio in Q4 2025, for an estimated $46,527,349
MORGAN STANLEY removed 3,694,724 shares (-61.3%) from their portfolio in Q4 2025, for an estimated $33,215,568
D. E. SHAW & CO., INC. added 3,102,664 shares (+139.2%) to their portfolio in Q4 2025, for an estimated $27,892,949
BAKER BROS. ADVISORS LP removed 2,746,674 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $24,692,599
ARK INVESTMENT MANAGEMENT LLC added 2,288,146 shares (+19.2%) to their portfolio in Q4 2025, for an estimated $20,570,432
VANGUARD GROUP INC added 1,965,181 shares (+17.8%) to their portfolio in Q4 2025, for an estimated $17,666,977
BLACKROCK, INC. added 1,878,957 shares (+18.3%) to their portfolio in Q1 2026, for an estimated $24,088,228

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$NTLA Price Targets

Multiple analysts have issued price targets for $NTLA recently. We have seen 13 analysts offer price targets for $NTLA in the last 6 months, with a median target of $17.0.

Here are some recent targets:

Mitchell S. Kapoor from HC Wainwright & Co. set a target price of $25.0 on 05/13/2026
William Pickering from Bernstein set a target price of $17.0 on 05/13/2026
David Nierengarten from Wedbush set a target price of $12.0 on 05/12/2026
Whitney Ijem from Canaccord Genuity set a target price of $49.0 on 05/12/2026
Terence Flynn from Morgan Stanley set a target price of $15.0 on 04/28/2026
Silvan Turkcan from Citizens set a target price of $30.0 on 04/28/2026
Salveen Richter from Goldman Sachs set a target price of $9.0 on 04/28/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.